I most certainly never said that. Nor am I afraid of critical...

I most certainly never said that. Nor am I afraid of critical discussion. What I have found though across my time on HotCopper is a preponderance of "experts" with no skin in the game. The "experts" who hold can easily have their bias accounted for. To be fair, it's dangerous to take anyone's advice here seriously and it should only use it as a basis for further research if warranted.

Beyond all that and engaging in the discussion at hand, I would suggest that investors have enough time in the most limited version of the patent window to do well. I also feel that the potential for generics in this space is much more complex than that of a pharmaceutical product. Not due to ability to replicate, rather due to professional practise and the specific sector this product is aimed at. I do think that cosmetic use has a danger of generic competition out of patent however.

But please be wary of my holder bias!